216 related articles for article (PubMed ID: 30804272)
1. Clinical significance of fibroblast growth factor-23 and soluble alpha klotho in different stages of chronic kidney disease.
Khodeir SA; Okda HI; Abdalal HM
Saudi J Kidney Dis Transpl; 2019; 30(1):108-118. PubMed ID: 30804272
[TBL] [Abstract][Full Text] [Related]
2. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
[TBL] [Abstract][Full Text] [Related]
3. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
[TBL] [Abstract][Full Text] [Related]
4. Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23.
Scholze A; Liu Y; Pedersen L; Xia S; Roth HJ; Hocher B; Rasmussen LM; Tepel M
J Clin Endocrinol Metab; 2014 May; 99(5):E855-61. PubMed ID: 24606097
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.
Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y
Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086
[TBL] [Abstract][Full Text] [Related]
6. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
7. [New markers of cardio-renal links in chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
[TBL] [Abstract][Full Text] [Related]
8. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
[TBL] [Abstract][Full Text] [Related]
9. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.
Liu Z; Zhou H; Chen X; Chen H; Wang Y; Wang T; Cai L; Hong Y; Ke H; Zheng J
Int Urol Nephrol; 2019 Mar; 51(3):503-507. PubMed ID: 30689182
[TBL] [Abstract][Full Text] [Related]
10. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N
PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031
[TBL] [Abstract][Full Text] [Related]
11. Circulating α-klotho levels in CKD and relationship to progression.
Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
[TBL] [Abstract][Full Text] [Related]
13. Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease.
Sawires HK; Essam RM; Morgan MF; Mahmoud RA
Nephron; 2015; 129(4):293-9. PubMed ID: 25766835
[TBL] [Abstract][Full Text] [Related]
14. Investigation on urinary and serum alpha klotho in dogs with chronic kidney disease.
Yi HJ; Lee JB; Lee KP; Oh YI; Song KH; Seo KW
BMC Vet Res; 2020 Jul; 16(1):246. PubMed ID: 32677951
[TBL] [Abstract][Full Text] [Related]
15. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
[TBL] [Abstract][Full Text] [Related]
16. Plasma s-Klotho is related to kidney function and predicts adverse renal outcomes in patients with advanced chronic kidney disease.
Liu QF; Ye JM; Yu LX; He AL; Sun Q; He DW; Li SS
J Investig Med; 2018 Mar; 66(3):669-675. PubMed ID: 29061648
[TBL] [Abstract][Full Text] [Related]
17. In chronic kidney disease, serum α-Klotho is related to serum bicarbonate and proteinuria.
Hage V; Pelletier S; Dubourg L; Drai J; Cuerq C; Lemoine S; Hadj-Aissa A; Laville M; Fouque D
J Ren Nutr; 2014 Nov; 24(6):390-4. PubMed ID: 25193108
[TBL] [Abstract][Full Text] [Related]
18. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
[TBL] [Abstract][Full Text] [Related]
19. High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease.
Sari F; Inci A; Dolu S; Ellidag HY; Cetinkaya R; Ersoy FF
J Investig Med; 2017 Feb; 65(2):358-362. PubMed ID: 27733443
[TBL] [Abstract][Full Text] [Related]
20. [Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance].
Milovanova LY; Mukhin NA; Kozlovskaya LV; Milovanov YS; Kiyakbaev GG; Rogova IV; Lebedeva MV; Androsova TV; Milovanova SY; Gil AY; Taranova MV
Vestn Ross Akad Med Nauk; 2016; 71(4):288-96. PubMed ID: 29297646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
